Payers and HTA agencies expect ever-increasing levels of evidence, speed, and strategic clarity when evaluating new health technologies. Meanwhile, internal teams are often stretched thin, facing mounting data complexity and global reimbursement variation.
AI offers a transformative opportunity to close these gaps: from accelerating evidence generation and automating dossier creation to simulating pricing negotiations and optimising launch strategies.
In this recorded webinar from 10 September 2025, CELforPharma faculty member Dr Stefan Walzer shared his insights on:
Where and how AI can be integrated in the market access process
How AI-based tools can reduce time and resource demands in dossier writing
What HTA bodies and payers really accept when it comes to AI-supported evidence
Live demonstration of use cases in pricing, objection handling, and launch planning